Literature DB >> 19010992

Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis.

T A Douglas1, S Brennan, S Gard, L Berry, C Gangell, S M Stick, B S Clements, P D Sly.   

Abstract

When do infants and young children with cystic fibrosis acquire infection with Pseudomonas aeruginosa? Can this be eradicated when first detected? Children <6 yrs of age participated in an annual bronchoalveolar lavage (BAL)-based microbiological surveillance programme in Perth, Australia. When P. aeruginosa was detected, an eradication programme using combination treatment with i.v., oral and nebulised antibiotics was undertaken. Repeat BAL was performed 3 months following treatment, to assess eradication success. P. aeruginosa was detected in 33 (28.4%) children; median (range) age at detection was 30.5 (3.3-71.4) months. P. aeruginosa was mucoid at detection in six (18.2%) out of 33 patients and associated with respiratory symptoms in 16 (48.5%) out of 33 children. In total, 26 children underwent eradication therapy, with P. aeruginosa eradicated in 20 (77%) out of 26 following one eradication cycle and in three (total 88%) additional children following a second cycle. Eradication was associated with a significant decrease in neutrophil elastase and interleukin-1beta in BAL fluid 12 months post eradication. Eradication of Pseudomonas aeruginosa infection is achievable in young children with cystic fibrosis for up to 5 yrs using combination i.v., oral and nebulised antibiotic therapy and is associated with reduced pulmonary inflammation 12 months post eradication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19010992     DOI: 10.1183/09031936.00043108

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  42 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Pseudomonas aeruginosa and post-tracheotomy bacterial respiratory tract infection readmissions.

Authors:  Christopher J Russell; Tamara D Simon; Mary R Mamey; Christopher J L Newth; Michael N Neely
Journal:  Pediatr Pulmonol       Date:  2017-04-25

3.  Early pulmonary disease manifestations in cystic fibrosis mice.

Authors:  Rebecca J Darrah; Anna L Mitchell; Cara K Campanaro; Eric S Barbato; Paul Litman; Abdus Sattar; Craig A Hodges; Mitchell L Drumm; Frank J Jacono
Journal:  J Cyst Fibros       Date:  2016-05-24       Impact factor: 5.482

4.  Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.

Authors:  Sonya L Heltshe; Nicole Mayer-Hamblett; Jane L Burns; Umer Khan; Arthur Baines; Bonnie W Ramsey; Steven M Rowe
Journal:  Clin Infect Dis       Date:  2014-11-25       Impact factor: 9.079

Review 5.  Targeting airway inflammation in cystic fibrosis in children: past, present, and future.

Authors:  Tacjana Pressler
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

6.  Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.

Authors:  Sinéad Weldon; Paul McNally; Noel G McElvaney; J Stuart Elborn; Danny F McAuley; Julien Wartelle; Abderrazzaq Belaaouaj; Rodney L Levine; Clifford C Taggart
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

Review 7.  Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa.

Authors:  Rustin R Lovewell; Yash R Patankar; Brent Berwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-01-24       Impact factor: 5.464

Review 8.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

9.  Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.

Authors:  S L Heltshe; U Khan; V Beckett; A Baines; J Emerson; D B Sanders; R L Gibson; W Morgan; M Rosenfeld
Journal:  J Cyst Fibros       Date:  2017-10-28       Impact factor: 5.482

10.  miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production.

Authors:  Sinéad Weldon; Paul McNally; Danny F McAuley; Irene K Oglesby; Christine L Wohlford-Lenane; Jennifer A Bartlett; Christopher J Scott; Noel G McElvaney; Catherine M Greene; Paul B McCray; Clifford C Taggart
Journal:  Am J Respir Crit Care Med       Date:  2014-07-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.